Conducted the first series of clinical trials showing the efficacy of interferon, leading to FDA approval for its use in treating two types of leukemia; first administration of synthetically produced recombinant interferon.
Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, Quesada JR, Gutterman JU. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res. 1985;45(6):2866-2872.
Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med. 1982;96(5):549-556.
Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980;93(3):399-406.
Currently conducting advanced clinical trials of several promising vaccines against leukemia, melanoma, and other cancers, using novel technologies that involve synthetic peptides, viruses, and stimulants of immune function.
Molldrem J, Lee P, Wang C, Felio K, Kantarjian H, Champlin R, Davis M. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6(9):018-23, 2000.
Rusakiewicz S, Kant S, Lizee G, Rabinovich B, Wieder E, Lu S, Hwu P, Molldrem J: CD8T cells with high avidity TCR-ab specifici for serine protease self-determinants for use in adoptive imunotherapy of human leukemia. J Immunology (178) 48.35, 2007.
Co-developed a peptide immunotherapeutic approach to therapy targeting the tumor-specific antigen epidermal growth factor variant III in patients with malignant glioma, resulting in a marked increase in median survival.
Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003;9(11):4247-4254.
Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson JH. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 2008;10(1):98-103.
Heimberger AB*, Sampson JH*, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE II, McLendon RL, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh J, Bigner DD (*Co-lead authors). Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28(31):4670-4673.
Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon II JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh J, Bigner DD, Heimberger AB. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011;13(3):324-333.